Results 161 to 170 of about 3,493 (205)

Low levels of influenza H5N1 HA and NA antibodies in the human population are boosted by seasonal H1N1 infection but not by H3N2 infection or influenza vaccination. [PDF]

mBio
Werner AP, Schneider CG, Akin EH, Hayes J, Fenstermacher KZJ, Rothman RE, Coughlan L, Pekosz A.   +7 more
europepmc   +1 more source

Multicentre, prospective, single-arm, non-controlled, open-label trial to evaluate the safety and efficacy of live attenuated influenza vaccine in paediatric patients with atopic dermatitis undergoing dupilumab therapy: a protocol. [PDF]

BMJ Open
Kobayashi T, Sato H, Nagasawa K, Hayata E, Tanaka S, Kurihara E, Yamamoto T, Nakano T, Ozawa Y, Yamaide F, Inoue Y, Suzuki S, Arima T, Tomiita M, Hamada H, Ishiwada N.   +15 more
europepmc   +1 more source

Influenza vaccine effectiveness from nine studies during drifted A(H3N2) subclade K predominance, Europe, September 2025 to January 2026. [PDF]

Euro Surveill
Lucaccioni H, Marques DF, Kirsebom F, Emborg HD, Hamilton M, Whitaker H, Bolt Botnen A, Bucholc M, Pozo F, Andrews N, Trebbien R, Hameed SS, Lauenborg Møller K, O'Doherty MG, Lopez-Bernal J, Morrison K, Cottrell S, Wilton S, Rose AM, Kissling E, European IVE group.   +20 more
europepmc   +1 more source

Comparison of 2 Doses vs 1 Dose in the First Season Children Are Vaccinated Against Influenza: A Systematic Review and Meta-Analysis.

JAMA Netw Open
Goldsmith JJ, Tavlian S, Vu C, Regan AK, Campbell PT, Sullivan SG.   +5 more
europepmc   +1 more source

Divergent phenotypic and functional roles of human T follicular helper cells from infancy to adulthood

Sureshchandra S, Kastenschmidt JM, Joloya EM, Wagoner ZW, Nair AK, Kim S, Zane N, Bhattacharya G, Monterroso AM, Cheng E, Sorn AM, Mitul MT, Beares H, Mendez G, Yates TB, Zhou F, Daugherty A, Thakur C, Brokstad KA, Trask D, Ahuja G, Zhong Q, Saligrama N, Cox RJ, Wagar LE.   +24 more
europepmc   +1 more source

Innate antiviral readiness drives the expansion of protective T stem cell memory against influenza

Tomic I, Ahern D, Tomalka J, Escalera A, Aydillo T, Pauly MD, Rouphael N, Lakdawala SS, Sadek N, Clutterbuck E, Singh N, Aley P, Robinson H, Marinou S, Hao SP, Fish M, Nakaya H, CHIM Study Group, Monaco C, Garcia-Sastre A, Pollard AJ, Tomic A.   +21 more
europepmc   +1 more source

Safety of live attenuated influenza vaccine (LAIV) in children with moderate to severe asthma [PDF]

Journal of Allergy and Clinical Immunology, 2020
Live attenuated influenza vaccine (LAIV) is recommended for annual influenza vaccination in children from age 2 years. However, some guidelines recommend against its use in children with asthma or recurrent wheeze due to concerns over its potential to induce wheezing.We sought to assess the safety of LAIV in children with moderate to severe asthma, and
Paul J Turner, Nick A Andrews, Louise Fleming   +2 more
exaly   +10 more sources

Live Attenuated Influenza Virus (LAIV) induces different mucosal T cell function in nonsmokers and smokers [PDF]

Clinical Immunology, 2012
Smokers are more susceptible to respiratory infections, including influenza. To explore the effect of smoking on influenza-induced responses within the nasal mucosa, we have developed a protocol using inoculation with live attenuated influenza virus ...
Ilona Jaspers, Terry L Noah, Luisa E Brighton   +2 more
exaly   +2 more sources

Effectiveness, tolerability and patient satisfaction of paediatric live-attenuated influenza immunization (LAIV) in routine-care in Germany: A case-control-study [PDF]

Trials in Vaccinology, 2013
SubjectPaediatric influenza is an unsolved public health problem, with high attack rates and spread from children to the chronically ill. The nasal live attenuated influenza vaccine (LAIV) is an attractive option for paediatric vaccination and provides ...
O Eickmeier, J Schulze
exaly   +2 more sources